An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will feature Chairman and CEO Dr. Garo Armen at two upcoming investor conferences. The HC Wainwright BioConnect Investor Conference is set for May 2, 2023, at 3:30 PM ET in New York City, where Dr. Armen will participate in a fireside chat. Additionally, he will engage in 1x1 meetings at the EF Hutton Global Conference on May 10, 2023. A live webcast of the fireside chat will be available on the company’s website, with a replay posted afterward. Agenus aims to improve cancer treatment through innovative therapies that enhance the immune response. The company operates advanced antibody discovery platforms and a GMP manufacturing facility to support clinical programs.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Agenus (NASDAQ: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences:
HC Wainwright BioConnect Investor Conference– Fireside chat presentation will be held in-person at NASDAQ Headquarters in New York City on Tuesday, May 2nd, 2023 at 3:30 PM ET
EF Hutton Global Conference – 1x1 meetings will be held in-person at the Plaza Hotel in New York City on Wednesday, May 10th, 2023
A live webcast of the fireside chat from the HC Wainwright BioConnect Investor Conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations. A replay will be posted following the event.
About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
